Hobart Private Capital, LLC Astrazeneca PLC Transaction History

Hobart Private Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Mar 11, 2024	SELL	$35.49 - $43.02 $592,789 - $718,563	-16,703 Closed	0 $0
Q4 2018 Mar 11, 2024	BUY	$36.86 - $41.49 $27,165 - $30,578	737 Added 4.62%	16,703 $634 Million
Q3 2018 Mar 11, 2024	SELL	$34.76 - $39.72 $385,210 - $440,177	-11,082 Reduced 40.97%	15,966 $632 Million
Q2 2018 Mar 11, 2024	SELL	$34.55 - $37.05 $205,917 - $220,817	-5,960 Reduced 18.06%	27,048 $950 Million
Q1 2018 Mar 11, 2024	BUY	$32.97 - $36.63 $1.09 Million - $1.21 Million	33,008 New	33,008 $1.15 Billion
Q4 2017 Mar 11, 2024	BUY	$32.09 - $34.78 $1.19 Million - $1.29 Million	37,220	37,220 $1.29 Billion

1,334

490M

4.99M

3.19M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $242B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Hobart Private Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Hobart Private Capital, LLC with notifications on news.